Edwards Lifesciences arrives at its Q1 2026 earnings release — due after the close today — with the most notable story running in the bears' retreat, not their advance.
Short interest has dropped sharply over the past month. It has fallen around 24% in 30 days to 1.65% of the free float, erasing a meaningful portion of the positioning built up through mid-March, when SI topped 12.6 million shares. The bulk of that unwind came in a single stretch around April 9-10, when short positions fell from above 11 million shares to roughly 9.3 million. Borrow costs are cheap — 0.46% annualised — and have eased about 10% over the past week, consistent with bears stepping back rather than facing a squeeze. Availability is tight at under 1%, though this reflects how small the lending pool is relative to the modest remaining short position, not active squeeze pressure. The ORTEX short score has drifted down to 29.9 from 30.7 two weeks ago, consistent with the broader derisking.
Options tell a different story. Put demand has climbed noticeably ahead of results, with the put/call ratio running at 1.51 — above its 20-day average of 1.44. The ratio has been elevated all month, holding mostly in the 1.55–1.70 range through the last two weeks of April before slipping slightly in the final session. This is not a panicked hedge — the z-score is only 0.53, well short of extreme — but put buyers have been more active than call buyers consistently since mid-April. The 52-week PCR range is 0.45 to 2.18, placing today's reading in the cautious middle ground.
The Street is broadly constructive. Most recent analyst moves in the past week were target raises: Barclays lifted to $110 from $104 while keeping its Overweight; BTIG raised to $100; Evercore bumped to $93. The outlier was Canaccord, which trimmed its target by $2 to $85 while staying at Hold. The mean target across the coverage universe is $97, implying around 19% upside from the current $81.22. The analyst consensus divergence factor ranks in the 94th percentile of the broader universe, reflecting unusually strong gap between where analysts and current price sit. Bulls point to TAVR revenue growing north of 10% year-over-year and TMTT nearly doubling, with management guiding 2026 TMTT revenue of $740-$780 million. Bears flag the margin miss in recent quarters — adjusted operating margin came in at 23.7% versus a 25.9% consensus expectation — and the risk that SG&A spending stays elevated as TMTT scales. The trailing PE sits at 26.4x on the snapshot multiple data, with EV/EBITDA at 20.1x and declining modestly over the past month. Revenue growth of 16.7% year-over-year in the most recent quarter gives the growth case genuine substance.
On the ownership side, JP Morgan Asset Management added the largest absolute position among top holders in the most recent quarter, increasing by 1.66 million shares to hold 3.9% of the company. Ninety One UK built by nearly 4.8 million shares to reach a 2.3% stake — the most aggressive incremental buying among the top-15 holders. Vanguard and BlackRock both added modestly, keeping their combined 21% anchor in place. On the insider side, CFO Scott Ullem sold approximately $1.04 million of stock in two tranches on April 9. VP Donald Bobo sold $1.82 million in early April. These are all low-significance disposals — largely routine-plan cadence — with no insider buying visible in the 90-day window to offset them. Net insider selling over 90 days runs to roughly $9 million, which is worth noting but not alarming at this market cap.
EW's last two quarterly prints both produced positive one-day moves: the February 2026 result gained 2.6%, and a more recent update in late April added 3.2%. Correlated peers have had a rougher week — SIBN and ATEC each fell more than 10%, while LIVN and PODD both dropped around 5%. EW's comparatively mild 0.4% weekly decline suggests relative resilience, but the peer weakness across med-tech is a broader macro backdrop the results will need to navigate.
The focus today is the margin trajectory: whether the SG&A pressure that dampened operating margins in recent quarters shows signs of easing, and whether TMTT revenue is tracking toward the top or bottom of that $740-$780 million guidance band.
See the live data behind this article on ORTEX.
Open EW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
